Glenmark Settles US Generic Drug Lawsuits for $7 Million

Glenmark Pharmaceuticals has agreed to pay $7 million to settle US lawsuits related to generic drugs. The settlement involves claims connected to cholesterol treatment drugs Zetia and Vytorin. The company denies the allegations and maintains no admission of liability. The cases involve major healthcare firms such as Humana and Centene.

Glenmark Pharmaceuticals announced on Monday that it will pay $7 million to resolve lawsuits in the United States concerning generic drugs.

The Mumbai-based pharmaceutical company disclosed in a regulatory filing that it had reached settlements in 2023 with three plaintiff groups, including Direct Purchaser, Retailer, and End-Payor Plaintiffs.

Despite the settlements, Glenmark emphasized that it denies all allegations against it, asserting that the agreements do not imply any admission of liability or illegality.

(With inputs from agencies.)